Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
MEI Pharma, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04745832CT.gov Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | — | Terminated | — | — | — |
NCT04673617CT.gov AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT04217317CT.gov CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04156828CT.gov Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | — | Terminated | — | — | — |
NCT04155840CT.gov Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Terminated | — | — | — |
NCT03886649CT.gov Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | — | Terminated | — | — | — |
NCT03997968CT.gov A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | — | Completed | — | — | — |
NCT03789240CT.gov Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03570892CT.gov Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Show 26 more trialsShow fewer
NCT03113422CT.gov Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy | — | Completed | — | — | — |
NCT03311126CT.gov Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT02257242CT.gov Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | — | Completed | — | — | — |
NCT02954406CT.gov A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT02626455CT.gov Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | — | Terminated | — | — | — |
NCT02187133CT.gov Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02342665CT.gov Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL | — | Completed | — | — | — |
NCT02155582CT.gov Copanlisib Pharmacodynamic Study | — | Completed | — | — | — |
NCT02059239CT.gov Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | — | Completed | — | — | — |
NCT02006485CT.gov Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | — | Completed | — | — | — |
NCT01900509CT.gov Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | — | Completed | — | — | — |
NCT01871675CT.gov Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | — | Completed | — | — | — |
NCT01594229CT.gov A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01458366CT.gov Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | — | Completed | — | — | — |
NCT01491841CT.gov IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01332968CT.gov A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | — | Completed | — | — | — |
NCT01294579CT.gov Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | — | Completed | — | — | — |
NCT01296256CT.gov Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). | — | Completed | — | — | — |
NCT01232556CT.gov A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy | — | Terminated | — | — | — |
NCT01059630CT.gov A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | — | Completed | — | — | — |
NCT01118845CT.gov Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT01133158CT.gov R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial | — | Completed | — | — | — |
NCT00825149CT.gov A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00864942CT.gov Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | — | Completed | — | — | — |
NCT00794638CT.gov A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01456351CT.gov Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bendamustine (this asset) | MEI Pharma, Inc. | P3 | BB · 70 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for Bendamustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 70 |
| Follicular Lymphoma | — | P4 | BB · 69 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bendamustine in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/bendamustine-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →